Literature DB >> 2783561

Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.

R K Puri1, W D Travis, S A Rosenberg.   

Abstract

The administration of interleukin 2 (IL-2) to mice and humans is limited by the induction of a dose-dependent increase in vascular permeability causing a vascular leak syndrome (VLS). We have investigated the impact of the injection of recombinant interleukin 1 alpha (IL-1 alpha) on the VLS induced by IL-2 by measuring the extravasation of 125I-albumin into tissues and by assessing wet and dry lung weights. IL-1 alpha alone did not induce any significant extravasation of radiolabeled albumin. IL-2 alone, however, caused a significant increase in the extravasation compared to control lungs. IL-1 alpha injection along with IL-2 significantly reduced the IL-2-induced extravasation of radiolabeled albumin [9,886 +/- 533 (SEM) cpm were observed in IL-2 and IL-1 alpha-treated lungs compared to 14,172 +/- 2,628 cpm in lungs treated with IL-2 alone (P less than 0.02)]. IFN-alpha in combination with IL-2 produced more severe vascular leakage than caused by IL-2 alone. IL-1 alpha also significantly decreased (P less than 0.05) the vascular permeability induced by the combination of IFN-alpha and IL-2. We observed 44,811 +/- 13,131 cpm in IFN-alpha- and IL-2-treated lungs compared to 18,350 +/- 2,622 cpm in IFN-alpha-, IL-2-, and IL-1 alpha-treated lungs. The IL-2- and IFN-alpha-induced increase in lung water weight was also reduced significantly by the addition of IL-1 alpha. The decrease in vascular leakage was dependent on the dose and timing of IL-1 alpha administered. When recombinant IL-1 alpha was given as a single i.p. injection, 24 h before the injection of IL-2 (or Hanks' balanced salt solution) or IL-2 and IFN-alpha no abrogation of the VLS was observed. Although IL-1 alpha decreased VLS significantly in mice treated with IFN-alpha and IL-2 the survival of mice was not improved by the simultaneous administration of IL-1 alpha. Histologically, treatment with IFN-alpha and IL-2 produced marked perivascular and intraalveolar edema which was completely eliminated by the addition of IL-1 alpha. However, some perivascular edema in IL-1 alpha-treated mice remained which was equivalent to that caused by IL-2 alone. Treatment of MCA-106 induced pulmonary metastases was enhanced by the administration of IFN-alpha and IL-2 together.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783561

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

Review 2.  Interleukin-1 as a possible agent for treatment of infection.

Authors:  J W van der Meer; M Vogels; J H Curfs; W M Eling
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 3.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

4.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

Authors:  R Baluna; J Rizo; B E Gordon; V Ghetie; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 12.779

5.  NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.

Authors:  A Orucevic; P K Lala
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

6.  Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross.

Authors:  Lisa E Gralinski; Martin T Ferris; David L Aylor; Alan C Whitmore; Richard Green; Matthew B Frieman; Damon Deming; Vineet D Menachery; Darla R Miller; Ryan J Buus; Timothy A Bell; Gary A Churchill; David W Threadgill; Michael G Katze; Leonard McMillan; William Valdar; Mark T Heise; Fernando Pardo-Manuel de Villena; Ralph S Baric
Journal:  PLoS Genet       Date:  2015-10-09       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.